Definium Therapeutics price target raised to $75 from $70 at Oppenheimer

RBC Capital reiterated an Outperform rating for Definium Therapeutics (DFTX) with a $66 price target, citing strong Phase III trial data for anxiety and depression treatments. Despite a 30% share price drop, RBC sees potential for approval and $2.5B peak revenue. Other analysts also raised price targets following positive trial results.

Definium Therapeutics (DFTX) stock rose 2.2% after JPMorgan initiated coverage with an Overweight rating and $84 price target, citing DT120 ODT's potential in neuropsychiatry. The company has 18 buy ratings and is targeting FDA submission in early 2027. Broader market gains also supported the rise.

Definium Therapeutics (DFTX) presented phase III data for DT120, showing statistically significant results in treating generalized anxiety disorder and major depressive disorder. The drug demonstrated placebo-adjusted improvements of 5.4, 5.1, and 8.1 points in respective studies, with rapid clearance. The company is preparing for pre-NDA talks with the FDA to discuss filing strategies. Response and remission rates were lower than phase II but still clinically meaningful.

Definium Therapeutics (DFTX) reported positive Phase 3 trial results for its LSD-based anxiety drug, DT120. The trial showed a 5.1-point improvement over placebo, similar to its previous trial. Psychedelic stocks often move together, and Definium's success could impact the broader sector. Hedge fund holdings of DFTX have increased, indicating growing institutional confidence.

Definium Therapeutics (DFTX) reported positive Phase III results for DT120 in treating anxiety, with 32% of patients showing significant improvement vs. 14% on placebo. The drug was well-tolerated, and the company plans to meet with the FDA in Q4, aiming for an NDA submission in early 2027. Definium has $1.1B in cash and is preparing for commercialization.

Definium Therapeutics (DFTX) reported positive Phase 3 trial results for DT120 ODT in treating generalized anxiety disorder. The stock has surged 184.53% year-to-date, with a fair value estimate of $71.65, suggesting a 46% undervaluation. The company faces risks due to its pre-revenue status and reliance on DT120's success, with key Phase 3 readouts expected in 2026.